Migraine – Epidemiology – Middle East and Africa
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s migraine forecast will answer the following questions:
- Of all people with migraine, how many in each country in the developed world have been formally diagnosed?
- Of all people diagnosed with migraine, how many in each country in the developed world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of migraine over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 26 migraine patient populations, including the following:
- Undiagnosed prevalent cases.
- Diagnosed nonprophylactically drug-treated prevalent cases.
- Undiagnosed chronic prevalent cases.
- High-frequency episodic migraine prevalent cases.
- Diagnosed prophylactically drug-treated prevalent cases.
- Diagnosed chronic prevalent cases.
- Medium-frequency episodic migraine prevalent cases.
- Episodic events.
- Total chronic prevalent cases.
- Total episodic prevalent cases.
Note: Coverage may vary by country.
